OQROGet OQRO Pro
Politician trade (Senate)

Abbott Laboratories (ABT)Sen. Alan Armstrong disclosed a sale $15K–$50K

Sen. Alan Armstrong disclosed a sale of Abbott Laboratories in the $15K–$50K range.

$15,001–$50,000
Reported range · official band, not an exact amount
116 days
Disclosure lag
Traded
Mar 27, 2026
Disclosed
Jul 21, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Jan 23, 2026Insider · First insider buy since Feb 2021CEO purchased ~$2.01M of ABT shares in the open market
  2. Jan 29, 2026CongressDisclosed purchase of ABT — reported range $1,001 - $15,000
  3. Feb 4, 2026Insider · 1 personInsiders: 2 purchases (~$1.1M)
  4. Feb 10, 2026CongressDisclosed partial sale of ABT — reported range $1,001 - $15,000
  5. Feb 13, 2026FDAFDA device clearance: Armada™ 14 NC PTA Catheter
  6. Feb 20, 2026Company filing · Form 8-K · Bylaws or charterChanged its bylaws, charter or fiscal year
  7. Feb 23, 2026Company filing · Form 8-K · Material agreementSigned an important agreement
  8. Mar 2, 2026Insider · 6 peopleInsiders: 6 sales (~$485K)
  9. Mar 9, 2026Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations
  10. Mar 13, 2026FDAFDA device clearance: Amplatzer™ Trevisio™ Intravascular Delivery System; 9-ATV06F45/609-ATV07F45/609-ATV07F45/809-ATV08F45/609-ATV08F45/809-ATV09F45/809-ATV10F45/809-ATV12F45/80
  11. Mar 19, 2026CongressDisclosed purchase of ABT — reported range $1,001 - $15,000
  12. Mar 26, 20265% stakeThe Vanguard Group reported a passive stake (13G)
  13. Mar 27, 2026 · this disclosureCongressDisclosed sale of ABT — reported range $15,001 - $50,000

What came next

  1. Apr 16, 2026Company filing · Form 8-K · ResultsReported its results
  2. Apr 16, 2026FDAFDA device clearance: Disposable Radiofrequency Cannula
  3. Apr 16, 2026CongressDisclosed sale of ABT — reported range $15,001 - $50,000
  4. Apr 20, 2026FDAFDA device clearance: EnSite™ X EP System
  5. Apr 23, 2026Insider · 1 day before an 8-KCFO purchased ~$201K of ABT shares in the open market
  6. Apr 24, 2026Company filing · Form 8-K · Executive change, Bylaws or charterChanged a top executive or board member, and changed its bylaws, charter or fiscal year (and 1 more item)“On April 24, 2026, Kevin Conroy was named to the Abbott Laboratories’ (“Abbott”) Board of Directors. On April 24, 2026, Abbott shareholders approved the adoption of the Abbott Laboratories 2026 Incentive Stock Program (the “2026 Program”) at the Annual Meeting of Shareholders.”
  7. Apr 24, 2026FDAFDA device clearance: OPTIS Mobile Next Imaging System (1014932); OPTIS Integrated Next Imaging System (1014933); Ultreon 3.0 Software Upgrade Kit (ULTR300001)
  8. Apr 24, 2026FDAFDA device clearance: Amplatzer TorqVue Delivery System
  9. Apr 27, 2026Insider · Their largest buy since 2018Director purchased ~$927K of ABT shares in the open market
  10. Apr 28, 2026FDAFDA device clearance: Anti-HCV Next
  11. Apr 29, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.5%
  12. May 7, 2026Insider · Their largest buy since 2019Director purchased ~$174K of ABT shares in the open market
  13. May 12, 2026FDARecall: Merlin" Patient Care System (PCS) software Merlin" PCS 3650 programmer Model 3330 software
  14. May 12, 2026CongressDisclosed sale of ABT — reported range $1,001 - $15,000
  15. May 15, 2026CongressDisclosed sale of ABT — reported range $1,001 - $15,000
  16. May 27, 2026Government · Federal Register noticeDrugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Syntest D.S. and Syntest H.S. Tablets; Withdrawal of Hearing Requests; Final Resolution of Drug Efficacy Study Implementation 7661
  17. May 27, 2026CongressDisclosed partial sale of ABT — reported range $1,001 - $15,000
  18. Jun 12, 2026Congress · 1 personMembers of Congress: 2 purchases
  19. Jun 16, 2026CongressDisclosed purchase of ABT — reported range $1,001 - $15,000
  20. Jun 17, 2026FDAFDA device clearance: Amplatzer TorqVue Exchange System
View the official recordSenate eFD periodic transaction report

How to read Senate eFD periodic transaction report

The STOCK Act is a 2012 US law that requires members of Congress, and some senior staff, to publicly report their stock trades, and those of their spouse and dependent children, within 45 days.

Full guide: What is the STOCK Act?

What else is on file for Abbott Laboratories

For Abbott Laboratories, OQRO holds 5 insider filings (SEC Form 4 or Form 144), 4 Congress trade reports and 82 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ABT page.

Other recent filings by Sen. Alan Armstrong

The full history of Sen. Alan Armstrong is on the profile page.

How this filing works

Other disclosures at Abbott Laboratories

Everything OQRO holds on this company is on its ABT page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data